INTRODUCTION
The autoimmune lymphoproliferative syndrome (ALPS) is characterized by early onset development of benign lymphadenopathy and splenomegaly, multilineage cytopenias due to autoimmune peripheral destruction and splenic sequestration of blood cells, and increased risk for B-cell lymphomas [1] [2] [3] . Patients typically accumulate a hallmark population of mature TCRαβ + T cells that are CD4 and CD8 negative 4, 5 . ALPS is caused by defects in proteins involved in the FAS pathway of lymphocyte apoptosis. Most (~65%) patients have mutations in the FAS (TNFRSF6/APO1/CD95) gene (ALPS-FAS), while a minority has mutations in the gene encoding FAS ligand (ALPS-FASLG) or caspase-10 (ALPS-CASP10) [6] [7] [8] [9] [10] [11] [12] . Germline mutations in CASP8 or somatic mutations in NRAS or KRAS cause ALPS-related syndromes currently classified separately [12] [13] [14] [15] The FAS gene contains 9 exons spanning 26Kb on chromosome 10q24.1 16 . The first 5
exons encode the extracellular portion of the protein containing three cysteine-rich domains that are involved in receptor trimerization and FASL binding required for triggering of the apoptotic signal. Exon 6 codes for the transmembrane domain and the intracellular portion is encoded by exons 7 through 9. The FAS death domain (DD), an 85-amino acid long structure encoded by exon 9, is required for FAS induced apoptosis of lymphocytes under physiological conditions 17 .
The majority of FAS defects associated with ALPS are heterozygous missense mutations that affect the intracellular death domain, allowing for the expression of a defective protein with a dominant-negative effect on the signaling pathway 7, 18 . These mutations demonstrate high penetrance for clinical symptoms including refractory cytopenias and an increased risk for lymphoma 2, 18 . However, evaluation of a large cohort of ALPS patients at our center has revealed a significant sub-population harboring mutations affecting the extracellular region of the protein, and these are commonly nonsense, or insertions, deletions and splice site mutations with frameshift ( Figure 1 ).
These mutations are predicted to abolish protein expression and hence are not expected to result in dominant-negative interference, and the mechanism by which this affects FAS apoptosis signaling is not clearly defined. FAS haploinsuficiency is one possible disease mechanism in ALPS associated with extracellular mutations but currently there are only very limited data supporting this mechanism 19, 20 . In fact, FAS haploinsuficiency was clearly demonstrated in only one ALPS patient to date, such that the prevalence, long term clinical impact and biochemical consequences are unknown 19 .
To understand the mechanism by which extracellular region FAS mutations disrupt the apoptotic machinery, we analyzed the functional impact of twenty-nine representative mutations across all regions of FAS using patient-derived B-cell lines. We demonstrate that most (eight of the eleven) mutations affecting the extracellular regions of the FAS receptor we studied are associated with haploinsufficiency. These mutations induced less severe disruption of the FAS mediated apoptosis signaling platform when compared to missense intracellular mutations, and the apoptotic defect could be rescued in vitro by FAS overexpression. These findings define haploinsuficiency as an ALPS-causing disease mechanism, in addition to the well-documented dominant-negative interference seen with intracellular mutations.
METHODS

Patient samples, cell culture and gene sequencing
All patients were studied at the National Institutes of Health under IRB approved protocols (93-I-0063 and 95-I-0066). Genomic DNA samples were PCR-amplified and sequenced as previously described 21 . For mRNA sequencing, cDNA was prepared from EBV transformed B-cells lines using RNeasy plus mini kit (Qiagen). To rule out the presence of contaminating DNA, RNA samples were subjected to PCR-amplification using intron-specific primers; the absence of amplified product (DNA) was confirmed by denaturing agarose gel electrophoresis (data not shown). cDNA was PCR-amplified (Forward: 5'-GTGAGGGAAGCGGTTTACGAGTGA-3', Reverse: 5'-AGTGGGGTTAGCCTGTGGATAGAC-3') and the products were subjected to sequencing (primer sequences available upon request). To determine the ratio of mutant to wild type FAS transcripts, cDNA was amplified and cloned into the pcDNA 3.0-HA vector (modified from pcDNA3.0 (Invitrogen)) with EcoRI and XhoI enzyme sites. After transformation, we picked 10-20 colonies and performed sequencing. Three samples with death domain mutations (D260N, Q276X, L294Dfs) were used as controls. For functional studies, EBV transformed B-cell lines from the patients were cultured in RPMI media with 10% FBS, 100 Units/ml Penicillin, 100 µg/ml Streptomycin, 2mM L-Glutamine (Gibco, Invitrogen).
Apoptosis measurement
EBV-transformed B-cells (200,000/well) were aliquoted in triplicate into 96 well plates and cultured with or without APO-1-3 (1 µg/ml) (ENZO Life Sciences) in the presence of protein A (1 µg/ml). After 24 hours, cell loss was determined by measuring the loss of the mitochondrial transmembrane potential using 3,3'-Dihexyloxacarbocyanine iodide 
Biomarkers
The quantification of IL-10, soluble Fas ligand, vitamin B 12, IL-18, TNF-α and TCRαβ + CD4 -CD8 -T cells on patient samples was performed as previously described 22 .
Statistical analysis
Data are represented as the mean ± S.E.M, except were noted. The statistical analyses were performed by unpaired Student's t-test or Mann-Whitney rank-sum test. Differences were considered significant when p<0.05.
RESULTS
FAS cell surface expression in ALPS-associated FAS mutations
We reviewed genetic data from 108 ALPS probands and identified 84 distinct mutations 
Low FAS expression is associated with apoptosis dysfunction due to impaired DISC formation
We next evaluated the functional impact of the 29 selected mutations in the FAS pathway by the treatment of EBV-transformed B-cell lines with the agonistic anti-FAS antibody APO-1-3 followed by cross linking. All cell lines with extracellular, transmembrane or intracellular mutations showed significant resistance to FAS-mediated cell death when compared to control cell lines (Fig. 3A-C) . The apoptotic defect could also be observed on primary cultured T cells (data not shown). Mutations in the extracellular domains resulted in milder apoptotic defects when compared to intracellular mutations, with median cell losses of 62% and 29%, respectively (Fig. 3D) . However, this difference did not reach statistical significance (p=0.17), likely due to the large data spread in the extracellular group and the limited sample number in each group. (Fig.4 B and C) , the extracellular mutations (Fig. 4A) showed consistent but more limited impairment in FADD (p=0.032) and caspase-8 (p=0.02) recruitment to the signaling complex, based on multiple experiments (Fig. 4D ).
These data demonstrate that extracellular mutations with low FAS expression attenuate downstream signaling and impair apoptosis, although to a lesser extent when compared to the intracellular mutations, and confirm interference of apoptosis by haploinsufficiency at the molecular level. 
Different mechanisms mediate low FAS expression
To gain insight into the mechanism(s) responsible for low cell surface FAS protein expression associated with extracellular FAS mutations, we first evaluated mRNA stability of mutant and wild type alleles by performing FAS cDNA cloning followed by sequencing. Although rare mRNAs harboring premature stop codons escape the degradation pathway, most transcripts containing a premature stop codon followed by a spliceable intron undergo nonsense-mediated mRNA decay (NMD) 23 . Accordingly, we detected almost exclusively wild type FAS cDNA in cells with the E45X, C63X, Y91X
and C149Nfs mutations (Table 1) , suggesting these mutated transcripts underwent NMD.
However, the nonsense mutations A16X, L18X, W176X, R250X, L294X and F133Ifs and, as expected, the missense L7P and C135Y, allowed both wild-type and mutant allele expression at varying ratios, suggesting that alternative mechanisms other than NMD also lead to low FAS expression seen with specific extracellular FAS mutations. 
Ectopic expression of L18X and F133Ifs in 293 T cells resulted in small amounts
of truncated proteins that did reach the cell surface (Fig. 5 and data not shown) . L16X is believed to behave in a similar manner. W176X also resulted in a short protein missing the transmembrane region that did not anchor on the cell surface ( Fig. 5 and data not shown). Interestingly, ectopic expression of R250X and L294X resulted in subnormal surface expression of the mutant FAS (Fig. 5) , similar to that observed in the EBV B-cell lines (Fig. 2) . These findings suggest that these two latter mutations may result in a combination of haploinsufficiency and dominant-negative inhibition.
L7P is located in the signal peptide, and it is plausible that impaired intracellular trafficking to the endoplasmic reticulum (ER) and Golgi apparatus prevents normal surface FAS expression, as it has been demonstrated for other proteins( 24, 25 . However, we could not detect any clear accumulation of FAS in the ER or Golgi by confocal microscopy (data not shown). These experiments were complicated by the fact that the mutation is heterozygous, such that 50% of the proteins are expected to traffick normally.
Lastly, C135Y affects a cystein residue within the third cysteine-rich domain, possibly resulting in an abnormally folded protein. Ectopic expression of this mutant did result in surface FAS expression, but at lower levels as compared to controls (Fig. 5 ).
Taken together these data suggest that haploinsufficiency associated with extracellular mutations can diminish FAS expression by inducing NMD, protein instability and, potentially, abnormal intracellular trafficking. 
Clinical and laboratory findings in patients with haploinsufficient alleles
We next analyzed the impact of the different FAS mutations on clinical and laboratory parameters in ALPS patients. Extracellular mutations are known to result in lower penetrance and variable expressivity, and these were not re-addressed in this study 18, 26 .
We evaluated recently described biomarkers associated with FAS mutations, including percentage of TCRαβ + CD4 -CD8 -(DNT) T cells as well as levels of soluble FAS ligand, IL-10, IL-18, TNF-α and vitamin B12 27, 28 . No statistically significant differences were noticed between patients with null extracellular or missense intracellular mutations (Fig.   6 ). However, one additional clinical finding that appeared to distinguish the two groups was the absence of lymphomas in patients with extracellular FAS mutations. Among over 189 patients from108 families with FAS mutations in the NIH cohort, all 21 lymphomas documented to date occurred in patients with intracellular mutations 29 . Additionally, lymphoma occurred in one patient with a somatic mutation in NRAS 14 . This finding suggests that the residual apoptotic function observed in haploinsufficiency-associated extracellular mutations may translate clinically not only into lower penetrance and expressivity but also into a lower risk for lymphomagenesis.
Overexpression of FAS in haploinsufficient samples corrects the apoptotic defect
To conclusively demonstrate haploinsufficiency as a disease mechanism, we transfected YFP-tagged wild type FAS or an empty GFP-expressing plasmid into selected EBVtransformed cell lines that showed reduced FAS expression and reduced sensitivity to FAS-induced cell death. Transfection efficiency ranged from 10-25% (data not shown).
Forty-eight hours after transfection we measured cell surface FAS expression by flow cytometry on live-gated GFP+ or YFP+ transfected cells (Fig. 7) . Cell surface FAS expression was increased after transfection with YFP-FAS, and this corrected the apoptotic defect, as compared with control GFP-transfected cells and normal controls. These results suggest that the level of surface FAS expression is a crucial determinant of the sensitivity to FAS-induced cell death. Haploinsufficiency has been commonly reported for genes involved in non-linear signaling processes, such as DNA transcription and assembly of macromolecular complexes 34 . Accordingly, productive FAS signaling requires the assembly of large signaling platforms on the cell surface 35 . This is thought to be required to concentrate pro-caspase-8 in close proximity allowing for self-cleavage, activation and propagation of the apoptotic signal 36, 37 . Thus, lower amounts of surface FAS may prevent the formation of a critical threshold of these complexes resulting in a disrupted apoptotic signal. Indeed, we showed that DISC formation is adversely affected in most of these patients, although to a lesser extent than in patients with intracellular mutations.
The milder nature of the apoptotic defect seen in haploinsufficiency-associated FAS mutations can be molecularly explained by the fact that the intact allele will allow expression of normal FAS proteins on the cell surface, which will presumably preassociate through their PLAD domains and form functional trimers, albeit at levels roughly 50% that seen in healthy controls. In contrast, missense intracellular mutations with dominant-negative effect will result in the incorporation of mutant proteins in 7 out of 8 FAS trimers on the cells surface, rendering them non-functional.
The residual FAS function seen in ALPS patients with haploinsufficiencyassociated extracellular mutations can potentially explain the incomplete clinical penetrance and variable expressivity, typical also of other diseases associated with haploinsufficient alleles 18, 20, 30, 34 . More strikingly, the absence of lymphoma cases to date in patients with FAS EC mutations suggests that this level of residual FAS function may be sufficient for tumor suppression, placing these patients at a lower cancer risk (3, 29) .
However, further long term follow up of ALPS patients at our and other centers will be necessary to fully substantiate this initial observation.
It is plausible that modifying factors including genetic, epigenetic or environmental, may make a larger contribution to disease phenotype in patients with EC mutations as compared to more severe dominant-negative mutations. Along these lines, Magerus-Chatinet et al. demonstrated in recent work that a group of ALPS patients with low-penetrance EC mutations present with a somatic event in the second FAS allele in double-negative T cells, and this was associated with the presence of clinical symptoms 38 .
Lastly, one can also speculate that the definition of haploinsufficiency as a common disease mechanism in ALPS makes gene therapy a future possibility for this group of patients, based on the finding that increasing FAS cell surface expression can reestablish normal apoptosis. In contrast, the current approach of viral vector gene insertion would likely not be effective in correcting the apoptotic defect associated with dominantnegative FAS mutations.
